GSK-3

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

GSK-3

GSK-3 related products

Cat No.	Product Name	CAS No.	Product Description
V69839	(E/Z)-GSK-3β inhibitor 1	3367-88-2	(E/Z)-GSK-3β inhibitor 1 is the racemate of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1.
V0224	1-Azakenpaullone (1-Akp)	676596-65-9	1-Azakenpaullone(1-Akp), an analog of kenpaullone, is a novel, ATP-competitive and selective inhibitor of GSK-3β (glycogen synthase kinase 3β) with potentialantidiabetic and neuroprotective activities.
V0228	BIO-acetoxime (GSK-3 Inhibitor X; BIA)	667463-85-6	BIO-acetoxime (also known asGSK-3 Inhibitor X;BIA),a synthetic derivative of a compound from the Mediterranean mollusk Hexaplex trunculus, is a novel, potent and selective dual inhibitor of GSK3α/β (glycogen synthase kinase-3) with potentialanti-infection andanticonvulsant as well as anticancereffects.
V69859	AChE/BACE1/GSK3β-IN-1	2866066-81-9	AChE/BACE1/GSK3β-IN-1 is an orally bioactive triple inhibitor of AChE/BACE1/GSK3β.
V0220	AZD1080	612487-72-6	AZD1080 is a selective, potent,orally bioactive, and brain permeable GSK3 (glycogen synthase kinase-3) inhibitor with neuroprotective effects.
V0219	AZD2858	486424-20-8	AZD2858 is a novel, potent, orally bioactive, and selective GSK-3 (glycogen synthase kinase-3) inhibitor with the potential to be used in fracture healing.
V0213	CHIR-98014	252935-94-7	CHIR-98014 (also known as CT-98024) is a novel, potent, reversible, cell-permeable inhibitor of GSK-3 (glycogen synthase kinase-3) with potential anti-diabetic activity.
V3199	CP21R7	125314-13-8	CP21R7 (also known CP21) is a potent and highly selectiveGSK-3βinhibitor that can potently activate canonical Wnt signalling with IC(50) of 0.6nM for GSK-3β.
V3531	GSK-3 inhibitor 1	603272-51-1	GSK-3 inhibitor 1 is a novel and potent inhibitor ofGSK-3 (Glycogen synthase kinase-3).
V89047	GSK-3 inhibitor 6	1772823-37-6	GSK-3 inhibitor 6 (2) is a CNS-permeable GSK-3 inhibitor with IC50 values of 29 nM and 24 nM for GSK-3α and GSK-3β, respectively.
V0221	AR-A014418 (SN-4521; GSK 3β inhibitor VIII)	487021-52-3	AR-A014418 (AR 0133418; SN4521; GSK-3β inhibitor VIII; AR 014418) is a novel, potent, ATP-competitive, and selective inhibitor of GSK3β (Glycogen Synthase Kinase 3β) with the potential for neurodegenerative diseases.
V69844	GSK-3β inhibitor 14	863004-48-2	GSK-3β inhibitor 14 (Compound 6i), a benzothiazazone analogue, is a weak GSK-3β inhibitor (IC50 >100 μM).
V69842	GSK3-IN-4	748145-19-9	GSK3-IN-4 (compound 0715) is a potent GSK3 inhibitor.
V0226	IM-12	1129669-05-1	IM-12, anindolylmaleimide analog, is a novel, potent, cell-permeable and selective inhibitor of GSK-3β (glycogen synthase kinase-3β) withpotential neuroprotective effects.
V0223	LY2090314	603288-22-8	LY2090314 (LY-2090314) is a novel and potent GSK-3 (glycogen synthase kinase-3) inhibitor for GSK-3α/β with potential antitumor activity.
V69854	SAR502250	503860-57-9	SAR502250 is a specific, ATP-competitive, orally bioactive and BBB (blood-brain barrier) permeable (penetrable) GSK3 inhibitor (antagonist) with IC50 of 12 nM for human GSK-3β.
V0212	SB216763	280744-09-4	SB216763 is a novel, potent and selective GSK-3 (glycogen synthase kinase-3) inhibitor with anti-inflammatory activiity and neuro-protective effects as it canpromote DNA repair in ischemic retinal neurons.
V0222	TDZD-8 (NP-01139)	327036-89-5	TDZD-8(NP01139; GSK3 Inhibitor I) is a novel, potent and non-ATP competitive GSK-3β (glycogen synthase kinase-3beta) inhibitor with the potential for treating neurodegenerative diseases such as PD (parkinson disease).
V0214	TWS119	601514-19-6	TWS119, apyrrolopyrimidine compound, is a novel, potent and selective/specific GSK-3β (Glycogen synthase kinase-3β) inhibitor with potentialusefulness for in vivo stem cell biology and therapy.
V0211	Laduviglusib (CHIR99021)	252917-06-9	Laduviglusib (CHIR-99021; CT99021; CT 99021) is a novel, potent and orally bioavailable inhibitor of GSK-3α/β (glycogen synthase kinase 3α/β) with the potential to treattype 2 diabetes.